No Data
Tesla plans to launch FSD in China in the first quarter of next year. Institutions say that the intelligent driving industry has reached a critical point.
On September 5, Tesla released its roadmap and expects to launch the Full Self-Driving (FSD) system in China and Europe in the first quarter of 2025, subject to regulatory approval. Ma Liang, from Anxin Securities, believes that recently multiple policies have been issued to support the development of smart driving. Combined with car companies actively promoting Urban NOA implementation, the turning point for the smart driving industry has arrived, and it is recommended to pay attention to relevant opportunities.
chongqing zhifei biological products' 23-valent pneumonia vaccine joins the "price reduction group" just one year after its launch.
①Chongqing Zhifei Biological Products' 23-valent pneumococcal polysaccharide vaccine has been reduced by nearly 30% in the listing price in provinces such as Jiangsu and jilin; ②Currently, the pneumococcal vaccine market in China is showing a competitive situation of fierce competition between overseas MNCs and domestic enterprises, while more and more companies are entering this field; ③Industry experts believe that in order to gain market share, companies can only choose to actively reduce prices.
The largest batch within the year! 117 domestic games have been approved for release, including NetEase and other listed game companies.
Following the approval of 15 imported games at the beginning of the month, 117 domestic games were issued with licenses this month, making it the month with the highest number of domestic game licenses issued so far this year.
The batch issuance of the quadrivalent HPV vaccine has dramatically decreased, and chongqing zhifei biological products' revenue and net profit have both declined. Interpretation of the financial report.
① Chongqing Zhifei Biological Products reported a decrease in revenue and net income for the first half of the year due to a decline in sales of its main product. ② The batch issuance of Merck's quadrivalent HPV vaccine, which the company represents, decreased by over 90% year-on-year. ③ As the development of domestically-produced nine-valent HPV vaccine accelerates, the company's pressure will further increase.
The recovery of the live pig market, ST Tianbang H1 turns loss into profit, and the pre-reorganization progresses as the company's debt decreases | interpretations
①ST Tianbang achieved a net income of 0.174 billion yuan after deducting non-recurring items in Q2, compared to a net loss of 0.455 billion yuan after deducting non-recurring items in Q1, indicating a clear improvement in the main business performance; ② The company's food business grew significantly during the reporting period, but it is still in a loss-making state; ③ The company made certain progress in reducing its liabilities, with total liabilities decreasing by 3.577 billion yuan from the beginning of the year, and the liability ratio decreased by 8.33 percentage points.
Gross margin halved and investment income is poor luoyang xinqianglian slewing bearing H1 turned to a loss|interpretations
①The decline in revenue year-on-year, the stock price of the investment target dropped, and the assets shrank, causing the star stock luoyang xinqianglian to report a worsened loss in the mid-year report compared to the first quarter; ②In response, the company stated that it will further increase new product technology research and development innovation, and deepen its market expansion and optimization of the supply chain management.